HighTide Therapeutics, Inc. announced that it will receive CNY 79,000,000 in an equity round of funding on January 18, 2019. The transaction will include participation from returning investor, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SZSE:002399). The transaction has been approved at the 16th session of the investor's 4th directorate.